Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma

Clin Cancer Res (2018) 24 (6): 1296–1304.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Comparison of the efficacy and safety of domestically produced tislelizumab, camrelizumab, and imported pembrolizumab in the treatment of advanced NSCLC: a real-world retrospective study
  • Jia Hu
  • MengTing Li
  • ZeYu Xie
  • JiSheng Chen
Clinical and Translational Oncology (2024)
Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer
  • Mengfei Cheng
  • Fang Yang
  • Yanchao Yang
  • Xinyue Gao
  • Yang Yu
  • Nan Wang
  • Xinyu Luo
  • Shuo Zhang
  • Shuai Jiang
  • Mei Dong
Cancer Chemotherapy and Pharmacology (2024) 93 (1): 31.
Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response
  • Ziqiang Chen
  • Xiaobing Wang
  • Zelin Jin
  • Bosen Li
  • Dongxian Jiang
  • Yanqiu Wang
  • Mengping Jiang
  • Dandan Zhang
  • Pei Yuan
  • Yahui Zhao
  • Feiyue Feng
  • Yicheng Lin
  • Liping Jiang
  • Chenxi Wang
  • Weida Meng
  • Wenjing Ye
  • Jie Wang
  • Wenqing Qiu
  • Houbao Liu
  • Dan Huang
  • Yingyong Hou
  • Xuefei Wang
  • Yuchen Jiao
  • Jianming Ying
  • Zhihua Liu
  • Yun Liu
npj Precision Oncology (2024) 8 (1)
Prognostic biomarkers for immunotherapy in esophageal cancer
  • Xu Tong
  • Meiyuan Jin
  • Lulu Wang
  • Dongli Zhang
  • Yuping Yin
  • Qian Shen
Frontiers in Immunology (2024) 15
Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma
  • Wenyan Gao
  • Shi Liu
  • Yenan Wu
  • Wenqing Wei
  • Qi Yang
  • Wenxin Li
  • Hongyan Chen
  • Aiping Luo
  • Yanfeng Wang
  • Zhihua Liu
eBioMedicine (2024) 105: 105177.
Tumor mutation load better predicts the prognosis of patients treated with immune checkpoint inhibitors in upper gastrointestinal cancers: A systematic review and meta‐analysis
  • Chenghao Ma
  • Qiong Teng
  • Liang Shang
  • Fengying Du
  • Leping Li
Cancer Reports (2024)
miR-378a-5p exerts tumor-suppressive effects on esophageal squamous cell carcinoma after neoadjuvant immunotherapy by downregulating APOC1/CEP55
  • Yang Pengjie
  • Jia Rong
  • Ning Pengfei
Scientific Reports (2024) 14 (1)
A machine learning radiomics based on enhanced computed tomography to predict neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma
  • Jia-Ling Wang
  • Lian-Sha Tang
  • Xia Zhong
  • Yi Wang
  • Yu-Jie Feng
  • Yun Zhang
  • Ji-Yan Liu
Frontiers in Immunology (2024) 15
Neoadjuvant Treatment in Locally Advanced Thyroid Carcinoma
  • Víctor Navas Moreno
  • Fernando Sebastián Valles
  • Marcos Lahera Vargas
  • Berta Hernández Marín
  • Elena Carrillo López
  • Mónica Marazuela
  • José Luis Muñoz de Nova
Journal of Clinical Medicine (2024) 13 (19): 5769.
Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial
  • Zixiang Wu
  • Chuanqiang Wu
  • Jing Zhao
  • Cong Wu
  • Haixian Peng
  • Qi Wang
  • Rui Bai
  • Xuefeng Fang
  • Hong He
  • Hong Shen
  • Ming Wu
eClinicalMedicine (2024) 71: 102579.
Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions
  • Yi Zhang
  • Zheng Li
  • Ying Huang
  • Yong Xu
  • Bingwen Zou
Expert Review of Clinical Immunology (2024) 20 (8): 971.
Advancements in the research of immune checkpoint inhibitors for the treatment of advanced esophageal squamous cell carcinoma
  • Mengfei Sun
American Journal of Cancer Research (2024) 14 (5): 1981.
Reactive cutaneous capillary endothelial proliferations of the eyelids induced by camrelizumab: A case report
  • Xuecong Zhou
  • Xiaoming Yan
  • Yuan Wu
Biomedical Reports (2024) 20 (3)
Immunotherapy for advanced or recurrent hepatocellular carcinoma
  • Ying-Zhe Luo
  • Hong Zhu
World Journal of Gastrointestinal Oncology (2023) 15 (3): 405.
A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma
  • Xiaonan Shi
  • Yang Wang
  • Jianzhuang Ren
  • Xinwei Han
  • Yonghua Bi
BMC Cancer (2023) 23 (1)
Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1–Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis
  • Hao-Xiang Wu
  • Yi-Qian Pan
  • Ye He
  • Zi-Xian Wang
  • Wen-Long Guan
  • Yan-Xing Chen
  • Yi-Chen Yao
  • Ning-Yi Shao
  • Rui-Hua Xu
  • Feng Wang
Journal of Clinical Oncology (2023) 41 (9): 1735.
Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?
  • Ning Chen
  • Xiaoling Xu
  • Yun Fan
Therapeutic Advances in Medical Oncology (2023) 15
Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer
  • Jianfeng Zhu
  • Yanyan Yu
  • Jiaqi Mei
  • Shiyao Chen
  • Jiufei Li
  • Sicong Jiang
Frontiers in Immunology (2023) 14
Systemic treatments for resectable carcinoma of the esophagus
  • Wattana Leowattana
  • Pathomthep Leowattana
  • Tawithep Leowattana
World Journal of Gastroenterology (2023) 29 (30): 4628.
Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials
  • Yao Lu
  • Wenkang Wang
  • Feng Wang
Frontiers in Immunology (2023) 14
Molecular profiles of different PD-L1 expression in patients with esophageal squamous cell carcinoma
  • Songchen Zhao
  • Xintong Hu
  • Peiwen Zhou
  • Ang Li
  • Liguo Chen
  • Duo Wang
  • Jiaxue He
  • Yanfang Jiang
Cancer Biology & Therapy (2023) 24 (1)
A robust immune-related gene pairs signature for predicting the overall survival of esophageal cancer
  • Wei Zheng
  • Gaofeng Fang
  • Qiao Huang
  • Dan Shi
  • Biao Xie
BMC Genomics (2023) 24 (1)
Radiotherapy plus camrelizumab affects peripheral CD8 T-cell differentiation subsets expressing PD-1, TIGIT, and CTLA-4 in esophageal squamous cell carcinoma
  • Zhoubo Guo
  • Kunning Zhang
  • Xiaoying Wei
  • Yanqi Li
  • Xiaoxue Ma
  • Yang Li
  • Dong Han
  • Qingwu Du
  • Tian Zhang
  • Xi Chen
  • Hui Wei
  • Cihui Yan
  • Wencheng Zhang
  • Qingsong Pang
  • Ping Wang
Journal of Leukocyte Biology (2023) 113 (1): 11.
Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma
  • Shuwen Yang
  • Dongmei Ji
  • Fen Xue
  • Tongzhen Chen
  • Yu Wang
  • Qinhai Ji
Cancer Reports (2023) 6 (1)
Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial
  • Guozhen Yang
  • Xiaodong Su
  • Yuanheng Huang
  • Guangyu Luo
  • Zhiqiang Wang
  • Peiqiang Cai
  • Yating Zheng
  • Ting Bei
  • Mengli Huang
  • Yuezong Bai
  • Haoqiang He
  • Jin Xiang
  • Muyan Cai
  • Jiudi Zhong
  • Qiyu Guo
  • Xu Zhang
Journal of Translational Medicine (2023) 21 (1)
Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future
  • Yong Liu
World Journal of Gastroenterology (2023) 29 (34): 5020.
Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma
  • Zhihua Liu
  • Yahui Zhao
  • Pengzhou Kong
  • Yuhao Liu
  • Jing Huang
  • Enwei Xu
  • Wenqing Wei
  • Guangyu Li
  • Xiaolong Cheng
  • Liyan Xue
  • Yi Li
  • Hongyan Chen
  • Shuqing Wei
  • Ruifang Sun
  • Heyang Cui
  • Yongsheng Meng
  • Meilin Liu
  • Yang Li
  • Riyue Feng
  • Xiao Yu
  • Rui Zhu
  • Yenan Wu
  • Lei Li
  • Bin Yang
  • Yanchun Ma
  • Jiawei Wang
  • Wenjie Zhu
  • Dongjie Deng
  • Yanfeng Xi
  • Fang Wang
  • Hongyi Li
  • Shiping Guo
  • Xiaofei Zhuang
  • Xiaoyue Wang
  • Yuchen Jiao
  • Yongping Cui
  • Qimin Zhan
Cancer Cell (2023) 41 (1): 181.
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
  • Xiaofeng Chen
  • Xiang Xu
  • Danping Wang
  • Jinyuan Liu
  • Jing Sun
  • Mingjie Lu
  • Rui Wang
  • Bingqing Hui
  • Xiaofei Li
  • Chenchen Zhou
  • Min Wang
  • Tianzhu Qiu
  • Shiyun Cui
  • Nana Sun
  • Yang Li
  • Fufeng Wang
  • Cuicui Liu
  • Yang Shao
  • Jinhua Luo
  • Yanhong Gu
Journal for ImmunoTherapy of Cancer (2023) 11 (2): e005830.
Transarterial Chemoembolization for Refractory Hepatocellular Carcinoma Following Anti-angiogenic Therapy Combined with Immune Checkpoint Inhibitors: A Retrospective Single-center Analysis
  • Qimin Zhang
  • Jiajia Xu
  • Mengye Xiong
  • Yiqing Tan
Iranian Journal of Radiology (2023) 20 (2)
The Molecular Characterization of Genetic Abnormalities in Esophageal Squamous Cell Carcinoma May Foster the Development of Targeted Therapies
  • Ugo Testa
  • Germana Castelli
  • Elvira Pelosi
Current Oncology (2023) 30 (1): 610.
Long non-coding RNA PVT1 promotes tumor progression by regulating the Wnt pathway in human esophageal squamous cell carcinoma
  • Chengyun Li
  • Xiong Yue
  • Yitong Li
  • Chao Ma
  • Xinghua Wang
  • Junling Wang
Chinese Medical Journal (2022) 135 (15): 1861.
Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC‐ESCC2019): A multicenter, phase 2 study
  • Jun Liu
  • Jingpei Li
  • Wanli Lin
  • Di Shao
  • Lieven Depypere
  • Zhifeng Zhang
  • Zhuoyi Li
  • Fei Cui
  • Zesen Du
  • Yuan Zeng
  • Shunjun Jiang
  • Ping He
  • Xia Gu
  • Huai Chen
  • Hai Zhang
  • Xiaowei Lin
  • Haoda Huang
  • Wenqiang Lv
  • Weiming Cai
  • Wenhua Liang
  • Hengrui Liang
  • Wenxi Jiang
  • Wei Wang
  • Ke Xu
  • Weipeng Cai
  • Kui Wu
  • Toni Lerut
  • Junhui Fu
  • Jianxing He
International Journal of Cancer (2022) 151 (1): 128.
Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future
  • Le Li
  • Hao-Tian Liu
  • Yu-Xian Teng
  • Zhu-Jian Deng
  • Guan-Lan Zhang
  • Jia-Yong Su
  • Liang Ma
  • Jian-Hong Zhong
Expert Opinion on Investigational Drugs (2022) 31 (11): 1151.
Immune-based combination therapy for esophageal cancer
  • Huiling Wang
  • Yufei Xu
  • Fengli Zuo
  • Junzhi Liu
  • Jiqiao Yang
Frontiers in Immunology (2022) 13
Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade
  • Cihui Yan
  • Xiaoxue Ma
  • Zhoubo Guo
  • Xiaoying Wei
  • Dong Han
  • Tian Zhang
  • Xi Chen
  • Fuliang Cao
  • Jie Dong
  • Gang Zhao
  • Xuan Gao
  • Tao Wang
  • Yao Jiang
  • Ping Wang
  • Qingsong Pang
  • Wencheng Zhang
OncoImmunology (2022) 11 (1)
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
  • Jun Liu
  • Yang Yang
  • Zhichao Liu
  • Xiaolong Fu
  • Xiaoyue Cai
  • Hongxuan Li
  • Li Zhu
  • Yan Shen
  • Hong Zhang
  • Yifeng Sun
  • Hezhong Chen
  • Bentong Yu
  • Renquan Zhang
  • Jinchen Shao
  • Ming Zhang
  • Zhigang Li
Journal for ImmunoTherapy of Cancer (2022) 10 (3): e004291.
Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
  • Shuguang Ju
  • Chen Zhou
  • Junwen Hu
  • Yingliang Wang
  • Chaoyang Wang
  • Jiacheng Liu
  • Chongtu Yang
  • Songjiang Huang
  • Tongqiang Li
  • Yang Chen
  • Yaowei Bai
  • Wei Yao
  • Bin Xiong
BMC Cancer (2022) 22 (1)
Thalidomide for prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation
  • Geng Song
  • Fei‐Fei Zhang
  • Huai‐Dong Cheng
Australasian Journal of Dermatology (2022) 63 (2): 217.
The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy
  • Go Ikeda
  • Shun Yamamoto
  • Ken Kato
Expert Opinion on Drug Safety (2022) 21 (1): 55.
Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis
  • Chuan Zhang
  • Shu Qin
  • Zhong Zuo
Journal of Oncology Pharmacy Practice (2022) 28 (6): 1350.
A Risk Model Based on Immune-Related Genes Predicts Prognosis and Characterizes the Immune Landscape in Esophageal Cancer
  • Yan Xie
  • Ruimin Fu
  • Zheng Xiao
  • Gang Li
Pathology and Oncology Research (2022) 28
Cysteinyl-tRNA Synthetase 1 Promotes Ferroptosis-Induced Cell Death via Regulating GPX4 Expression
  • Wanfei Zhang
  • Xianzuan Lin
  • Shaogeng Chen
  • Yingkun Xu
Journal of Oncology (2022) 2022: 1.
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study
  • Jin-Ji Yang
  • Cheng Huang
  • Yun Fan
  • Hongming Pan
  • Jifeng Feng
  • Liyan Jiang
  • Xing-Ya Li
  • Xiao-Qing Liu
  • Jian-Ping Xiong
  • Yan-Qiu Zhao
  • Ying Cheng
  • Rui Ma
  • Jie Wang
  • Yina Wang
  • Yan-Hui Liu
  • Dong-Mei Lin
  • Tao Wang
  • Wei Shi
  • Jianjun Zou
  • Yi-Long Wu
Cancer Immunology, Immunotherapy (2022) 71 (6): 1393.
Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy
  • Yan Yan
  • Xijia Feng
  • Chengqiang Li
  • Toni Lerut
  • Hecheng Li
Chinese Medical Journal (2022) 135 (18): 2143.
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
  • Shengxiang Ren
  • Jianhua Chen
  • Xingxiang Xu
  • Tao Jiang
  • Ying Cheng
  • Gongyan Chen
  • Yueyin Pan
  • Yong Fang
  • Qiming Wang
  • Yunchao Huang
  • Wenxiu Yao
  • Rui Wang
  • Xingya Li
  • Wei Zhang
  • Yanjun Zhang
  • Sheng Hu
  • Renhua Guo
  • Jianhua Shi
  • Zhiwu Wang
  • Peiguo Cao
  • Donglin Wang
  • Jian Fang
  • Hui Luo
  • Yi Geng
  • Chunyan Xing
  • Dongqing Lv
  • Yiping Zhang
  • Junyan Yu
  • Shundong Cang
  • Zeyu Yang
  • Wei Shi
  • Jianjun Zou
  • Caicun Zhou
Journal of Thoracic Oncology (2022) 17 (4): 544.
Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
  • Meng Chen
  • Chenyan Li
  • Mingjun Sun
  • Yiling Li
  • Xuren Sun
Frontiers in Immunology (2022) 13
Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports
  • Zhe Zhang
  • Chang-Qing Zheng
World Journal of Clinical Cases (2022) 10 (29): 10550.
PD-1 Inhibitor Plus Chemotherapy Versus Chemotherapy as First-line Treatment for Advanced Esophageal Cancer: A Systematic Review and Meta-Analysis
  • Yao Lu
  • Mengli Xu
  • Lulu Guan
  • Yalan Yang
  • Yu Chen
  • Yuanyuan Yang
  • Feng Wang
Journal of Immunotherapy (2022) 45 (5): 243.
Toxic epidermal necrolysis during camrelizumab treatment for esophageal squamous cell carcinoma
  • Yuan Peng
  • Qian Yu
  • Xiaoyue Zhang
  • Chuan Zeng
  • Yan Zhou
  • Yusheng Huang
  • Zhenzhou Yang
Contact Dermatitis (2022) 86 (5): 417.
Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
  • Shengxiang Ren
  • Jianxing He
  • Yong Fang
  • Gongyan Chen
  • Zhiyong Ma
  • Jianhua Chen
  • Renhua Guo
  • Xiaoyan Lin
  • Yu Yao
  • Gang Wu
  • Quanren Wang
  • Caicun Zhou
JTO Clinical and Research Reports (2022) 3 (5): 100312.
  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept